An interim review of an HIV prevention trial in Africa has determined that a vaginal gel containing the drug tenofovir was no more effective than a placebo gel in preventing HIV infection in women (http://www.mtnstopshiv.org/node/3909).
Based on the recommendations of the independent data and safety monitoring board (DSMB) of the Vaginal and Oral Interventions to Control the Epidemic (VOICE) study, the investigators will discontinue the section of the trial that involved participants receiving the tenofovir or placebo gels but will continue with a group who is receiving a pill containing 2 drugs (tenofovir and another anti-HIV drug, emtricitabine) or placebo.
Friedrich MJ. HIV Trial Modification. JAMA. 2012;307(3):243. doi:10.1001/jama.2011.1976